Global Single-use Bioreactor Market Size

Single Use Bioreactor Market Analysis

The Global Single-use Bioreactor Market size is estimated at USD 1.47 billion in 2024, and is expected to reach USD 2.34 billion by 2029, growing at a CAGR of 9.70% during the forecast period (2024-2029).

The ongoing Covid-19 pandemic is expected to have a significant impact on the studied market. The market growth was hampered by the decline in sales by major players in the initial phase of the pandemic due to the shutdown and closure of the manufacturing sites. For instance, according to a press release titled "Single-use Lead Times up to 12 Months as COVID Takes Its Toll" by one of the global market players ABEC in May 2021, few manufacturers have waited up to 1 year for single-use equipment, while vendors who are expanding capacities, these projects took months to come online. Thus, the sales of single-use bioreactors were affected by the pandemic. However, single-use bioprocess materials and systems were considered essential resources for the creation and distribution of possible vaccines and treatments for the disease. And, these platforms were used to make innovative vaccines, such as mRNA, DNA, and viral vectors, and were generally constructed using single-use technologies due to the speed and flexibility required. In the article 'COVID-19 Drives Surge in Growth of Single-use Technologies' published in July 2022 it was mentioned that biopharmaceutical companies sought out adaptable technologies that could be swiftly brought online to mass produce vaccines against the SARS-CoV-2 virus. As a result, COVID-19 marked a turning point for single-use systems (SUS), with a sharp rise in demand for reusable and adaptable technology for industrial manufacture. Therefore, such factors mentioned above indicate that the Covid-19 pandemic has had a significant impact on the market studied.

Certain factors that are driving the market's growth include rapid adoption of single-use technologies (SUTs) by the industry, cost-effectiveness, lower downtime, and the launch of new products.

Furthermore, the inclination of the industry toward using singleuse bioreactors (SUBs) is currently being influenced by the criticality of the step, the value of the product, and the time for product development and production. Additionally, as per the article 'Advancing upstream biomanufacturing: continuous perfusion cell culture' published in July 2022 it was mentioned that initial continuous perfusion process development frequently takes more time than batch and fed-batch processes. However, once the procedure is in practice, productivity gains might counterbalance this. These benefits include enabling manufacturers to reach clinical production quantities more readily by allowing for lesser scale-up production operational volume requirements. And these benefits can be achieved using single-use bioreactors. Therefore, such advantages in manufacturing facilities that are gained by using single-use bioreactors are anticipated to contribute to market growth.

In the bioprocessing sector, SUBs has become a standard for both clinical and industrial batches. Thus, significant developments are being made in the single-use bioreactor segment which is also fuelling the market growth. For instance, in March 2021, Thermo Fischer Scientific launched the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. The 3,000 L and 5,000 L vessels in this product have the same footprint, with hardware that is simplified and optimized for perfusion cell culture procedures to assist conserve manufacturing suite space. Thus, such developments are anticipated to drive market growth over the forecast period.

Therefore, owing to the above-mentioned factors the market is predicted to witness growth over the forecast period. However, high regular recurring expenses may be involved which is anticipated to hinder the market growth.